Ann: IXUP Third Quarter FY21 Update and Appendix 4C, page-15

I think they've got a ?disruptive product with some proof of commercialisation (albiet insanely small revenues to the point where it's pre-revenue phase). They've got "bluechip" associations with Tekkcorp and the concacef deal; cash position seems okay but given the stage of the business cycle they are in I guess it's impossible to be confident they wouldn't raise capital (but theoretically they shouldn't be raising capital on the basis of the operating cash flow right now). Market cap doesn't really make sense to me but does suggest to me that the bigger holders are classifying this as a growth stock which isn't unreasonable.

I entered from a TA perspective and it's done well so far. Unstable markets right now does make it a little tricky to buy confidently around these levels, especially as it has average liquidity (but average daily traded volume is not that bad provided it stays constant and doesn't disappear as the trend develops) and it did dip 16% to recover completely intraday a day ago reflecting its underlying volatility/beta potential. If they secure more deals I could see this re-rating I guess, but I never let due diligence or emotion cloud the reality of the price action and would cut it in an instant if my system told me to.